002038.SZ
双鹭药业
SZSE · Healthcare · C 制造业 · CN
CNY 6.37
−10.03%Year over year
Reported trailing growth
- Revenue
- +1.3%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +178.1%
- Operating cash flow
- +493.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -15.9%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -34.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026